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Background
The long-term outcomes of adult patients with immune thrombocytopenic purpura (ITP) 
after splenectomy are not clear.
Methods
We retrospectively analyzed 31 patients who underwent splenectomy after diagnosis of 
ITP at our institution between 1990 and 2009. Long-term follow-up was defined as a fol-
low-up that lasted 1 year or more from splenectomy to the last follow-up.
Results
The overall response rate to splenectomy was 84%. However, the response rate at 6 and 
12 months decreased to 77% and 68%, respectively. During the 6 years of median fol-
low-up after splenectomy, 11 patients (35%) relapsed. The long-term response rate was 
55%. The long-term follow-up of 26 patients after responding to splenectomy showed 
that the median time from splenectomy to relapse was 19 months in the partial response 
(PR) group; however, there was no relapse after 9 months in the complete response (CR) 
group. Variables, including age, were not predictive of the long-term response after 
splenectomy. Additional treatment in patients who did not respond or relapsed after sple-
nectomy was mostly effective. After a median follow-up of 7 years (range: 1-25 years) 
from the diagnosis, there were 2 deaths, including one due to spontaneous bleeding after 
repair of duodenal ulcer perforation.
Conclusion
Although splenectomy is safe and effective, the response rate after splenectomy con-
tinuously decreases over time. The duration of response is different between the patients 
that achieved CR and those that achieved PR. Factors, including age, were not predictors 
of a response to splenectomy.
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INTRODUCTION
  Immune thrombocytopenic purpura (ITP) is an auto-
immune disorder characterized by accelerated destruction 
of platelets due to autoantibodies and insufficient production 
of platelets [1]. ITP is caused by the production of autoanti-
bodies directed to platelet surface proteins. The mechanism 
by which the platelet surface proteins become antigenic and 
stimulate the immune system is not clear. However, this 
action results in accelerated platelet destruction and sup-
pression of platelet production [1].
  In adults, ITP typically has an insidious onset, without 
preceding viral or other illnesses. Symptoms and signs vary 
from no symptoms to clinically significant hemorrhages. 
However, bleeding symptoms are uncommon unless the ITP 
is severe [2]. The diagnosis of ITP is based on clinical features 
and complete blood counts; other reactive causes of thrombo-
cytopenia should be excluded [2].
  Although patients presenting with clinically significant 
bleeding require emergency treatment and intravenous im-
munoglobulin therapy, the standard first-line treatment for 
patients without critical bleeding is oral corticosteroids. 
About 50% of patients respond to initial corticosteroid treat-
ment, but only 10-20% of patients have a sustained response 
[2].Korean J Hematol 2010;45:197-204.
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  As a second line treatment, patients with very severe 
thrombocytopenia (platelet counts ＜10,000/μL), those with 
a high risk of bleeding (platelet counts ＜30,000/μL), or 
those who require continuous corticosteroid treatment to 
maintain safe platelet counts are candidates for therapeutic 
splenectomy. The response rate to splenectomy varies from 
50% to 80% [3, 4]. A systematic review of splenectomy 
reported a complete response rate in 66% of patients with 
1.0% mortality after a laparotomy and 0.2% mortality after 
laparoscopy [3]. However, the long-term results after sple-
nectomy in patients with ITP are not clear.
  There is little information on the patients that fail to 
respond after splenectomy. Currently available treatments 
for patients with refractory ITP include danazol, azathio-
prine, vinca alkaloids, cyclophosphamide, cyclosporine, and 
rituximab; however, there is limited evidence on the efficacy 
of any treatment [5]. The recently developed thrombopoie-
tin-mimetic agents, such as romiplostim and eltrombopag, 
offer new options for managing patients with ITP that are 
refractory to splenectomy [6].
  The purpose of this study was to investigate the long-term 
outcomes of patients with ITP after splenectomy and to 
evaluate the results of additional therapy in patients that 
did not respond to splenectomy. In addition, we analyzed 
the predictive factors associated with a response to splenec-
tomy and the pharmacological therapy that was useful after 
failure of splenectomy.
MATERIALS AND METHODS
  After approval by the institutional review board, the pa-
tient database at Kyung Hee University Medical Center in 
Seoul, the Republic of Korea, was retrospectively reviewed 
to identify 44 adult (age≥16 years) patients with ITP that 
underwent splenectomy between March 1, 1990 and June 
1, 2009. Of the 44 patients, 31 patients having a follow-up 
time of more than 12 months were included in this study. 
All patients met the diagnostic criteria reported by the 
American Society of Hematology Practice Guidelines [7]. 
The medical records of these patients were reviewed for 
the clinical and laboratory information regarding their diag-
nosis, initial treatment, splenectomy, and post-splenectomy 
follow-up. The severity of bleeding at diagnosis was classified 
into four categories according to the severity: asymptomatic, 
minor purpura or easy bruisability, mucosal bleeding that 
might require clinical intervention, and severe life-threat-
ening bleeding. The severity of thrombocytopenia was classi-






9/L; and mild, 
＞50×10
9/L.
  All patients received oral corticosteroids 1 mg/kg/day for 
initial treatment, except for 4 patients that required a rapid 
increase in the platelet counts. Fourteen patients initially 
received intravenous immunoglobulin (IVIG) and were later 
started on steroids. The indications for splenectomy were: 
1) not responding to medical therapy for 4 weeks; 2) relapse 
during the tapering of steroids; 3) side effects to steroids; 
4) poor compliance with the medication. Patients with plate-
let counts less than 50×10
9/L were treated with IVIG before 
splenectomy. The size and weight of spleen were measured 
during surgery; however, this was limited in those cases 
involving a laparoscopic splenectomy. The platelet counts 
at 1 week, 1 month, 6 months, and 12 months after the 
splenectomy were assessed to determine the response to 
splenectomy. A response to the splenectomy was defined 
as a response at 1 month after splenectomy. The long-term 
response to splenectomy was defined as a response from 
12 months to the last follow-up. The correlation between 
gender, age at diagnosis, symptoms at diagnosis, platelet 
counts at diagnosis, anti-platelet antibody, response to 
pre-splenectomy treatment, reasons for splenectomy, age at 
splenectomy, platelet counts before splenectomy, time to 
splenectomy, methods of splenectomy, weight of the spleen, 
and the likelihood of a response after splenectomy were 
analyzed. In the patients that were unresponsive to splenec-
tomy, additional treatment with corticosteroids, IVIG, dana-
zol, vinca alkaloids, or a combination of these preparations 
were attempted.
1. Definitions of response to treatment and relapse
  The response criteria to pharmacological treatment were 
defined: complete response (CR), platelet counts ＞150×10
9/L 
for ≥4 weeks; partial remission (PR), platelet counts ≥50 
-150×10
9/L for ≥4 weeks; transient response for ＜4 weeks; 
and no response (NR), platelet counts ＜50×10
9/L for 4 weeks 
of therapy [8, 9]. The definitions were also used to define 
CR and PR after splenectomy. Non-responders to splenec-
tomy were defined as patients that failed to achieve platelet 
counts ≥50×10
9/L at any time after splenectomy. Relapse 




  The remission duration was determined in 26 patients 
that responded to splenectomy during the interval from the 
splenectomy to the date of relapse. The time to progression 
was defined in all 31 patients as the interval from the splenec-
tomy to the date of decrease of the platelet counts ＜50×10
9/L. 
Curves of the remission duration and time to progression 
were constructed using the life-table technique by Kaplan- 
Meier. Data on patients still in remission or that died were 
censored at the time of the last follow-up or death. The 
log-rank test was used for comparison of the remission dura-
tion between the CR and PR groups. For comparisons be-
tween groups, Fisher’s exact test was used for nominal data. 
Mann-Whitney U-test was performed for non-parametric 
data and t-test for parametric data. All P values were two-sid-
ed and statistical significance was defined as a P value＜0.05. 
All statistical analyses were carried out with SPSS software 
(SPSS, Inc., Chicago, IL, USA).Korean J Hematol 2010;45:197-204.
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Table 1. Patient characteristics at diagnosis.
Variables N=31 %
Age (years), median (range)   46 (14-74)
Gender
  Male   4 13
  Female 27 87
Initial presentation
  Asymptomatic   8 26
  Skin purpura or bruisability 15 48
  Clinically significant bleeding   8 26
Platelet count (×10
9/L)
a), median (range) 14 (1-72)
  Very severe   9 29
  Severe 14 45
  Moderate   2 6
  Mild   3 10
Anti-platelet antibody
  Positive   7 23
  Negative 16 52
  Unknown   8 25
Initial treatment
  PDL 16 52
  IVIG   2 6
  PDL+IVIG 13 42
Response to initial therapy
  Complete response   5 16
  Partial response 15 48
  No response 11 36
Thirty-one of the 44 patients who were available for follow-up for at
least 1 year were analyzed. The median follow-up duration was 7 
years (range: 1-25 years). No patients showed life threatening 









Abbreviations: PDL, prednisolone; IVIG, intravenous immunoglo-
bulin.
Table 2. Patient characteristics at splenectomy.
Variables N=31 %
Age (years), median (range)   46 (16-74)
Platelet count (×10
9/L), median (range)     9 (1-77)
Time to splenectomy (months),     5 (0-155)
 median (range)
Reasons for splenectomy
  Non-responders or relapse after        21 68
   tapering steroid
  Adverse effects to steroid          5 16
  Noncompliance to steroid          2 6
  Others
a)          3 10
Method of splenectomy
  Open         15 48
  Laparoscopy        16 52
Weight of spleen (g), median (range) 110 (37-400)
Accessory spleen
  Removed during splenectomy          3 10
  No accessory spleen        28 90
Perioperative complications          3 10
  Hemoperitoneum          2
  Wound abscess          1
The median follow-up duration after splenectomy was 6 years 
(range, 1-21 years).
a)Active pulmonary tuberculosis, splenectomized during subtotal 
gastrectomy, splenectomy was done before pregnancy.
RESULTS
1. Characteristics of patients at diagnosis
  The median age at diagnosis was 46 years (range: 14-74 
years). Four patients (13%) were males and 27 (87%) were 
females. Eight of the 31 patients (26%) were asymptomatic 
at diagnosis. Fifteen patients (48%) presented with minor 
purpura or easy bruisability and 8 patients (26%) with clin-
ically significant bleeding symptoms at diagnosis. None of 
the patients showed severe life-threatening bleeding symp-
toms at diagnosis. The median platelet count at diagnosis 
was 14×10
9/L (range: 1-72, missing data in 3 patients); 9 
patients (29%) were very severe, 14 patients (45%) were 
severe, 2 patients (6%) were moderate, and 3 patients (10%) 
were mild. Anti-platelet antibodies were positive in 7 patients 
(23%) and negative in 16 patients (52%, missing data in 
8 patients). Twenty patients (65%) had other medical con-
ditions, with 6 having 2 conditions: diabetes mellitus (N=5), 
hypertension (N=4), thyroid disease (N=4), iron deficiency 
anemia (N=3), stomach cancer (N=1), asthma (N=1), ulcer-
ative colitis (N=1), chronic hepatitis (N=1), alcoholic liver 
disease (N=1), intra-hepatic duct stone (N=1), coronary artery 
disease (N=1), ureter and renal stone (N=1), active pulmonary 
tuberculosis (N=1), and pregnancy (N=1). The median fol-
low-up duration was 7 years (range: 1-25 years) (Table 1).
2. Initial response to treatment before splenectomy
  Sixteen patients received steroids and 2 patients received 
IVIG for first line therapy. Thirteen patients received steroids 
and IVIG. Overall response was obtained in 20 patients (64%) 
with CR in 5 patients (16%) and PR in 15 patients (48%). 
Eleven patients (36%) had no response to initial therapy 
(Table 1).
3. Characteristics of patients at splenectomy
  The median age at splenectomy was 46 years (range: 16-74 
years). The median duration from diagnosis to splenectomy 
was 5 months (range: 0-155 months). The median platelet 
count before splenectomy was 9×10
9/L (range: 1-77×10
9/L). 
The median follow-up duration after splenectomy was 6 
years (range: 1-21 years). Twenty-one patients (68%) did 
not respond to corticosteroids or dependent on cortico-
steroids, 5 patients (16%) experienced severe side effects 
to steroids, and 2 patients (6%) had poor compliance with 
the medications. Other reasons for the splenectomy in the 
remaining 3 patients (10%) were: active pulmonary tuber-
culosis, a splenectomy performed during a subtotal gas-
trectomy in a patient with stomach cancer, and a splenectomy 
performed before pregnancy. Fifteen patients (48%) under-
went open splenectomy and 16 patients (52%) underwent 
laparoscopic splenectomy. The median weight of the spleen 
was 110 g (range: 37-400 g). An accessory spleen was found Korean J Hematol 2010;45:197-204.
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Fig. 1. Progression-free survival of all 31 patients after splenectomy. 
Median time of progression-free survival was 70 months.
Fig. 2. Kaplan-Meier curve of remission (CR+PR) duration in 26 
patients after responding to splenectomy. Median time from 
splenectomy to relapse was 19 months in PR patients. However, no 
relapse occurred after 9 months in CR patients. CR, complete response;
PR, partial response.
Table 3. Response status during the follow-up period after 
splenectomy.
Status 1 month 6 months 12 months
Last 
follow-up
Complete response 14 (45%) 14 (45%) 13 (42%) 13 (42%)
Partial response 12 (39%) 10 (32%)   8 (26%)   4 (13%)
Relapse    NA   4 (13%)   7 (22%) 11 (35%)
b)
Non-responders   5 (16%)
a)   3 (10%)   3 (10%)   3 (10%)
Overall response rate of splenectomy was 84% at 1 month and 55%
at long-term follow-up.
a)Two non-responders achieved complete response after 1 month of
follow-up; 
b)Nine patients relapsed within 24 months after splenec-
tomy, and 2 patients relapsed at 70 and 104 months, respectively.
Abbreviation: NA, not applicable.
in 3 patients (10%) during the surgery and was removed. 
Three patients (10%) had complications after the splenec-
tomy. Two patients underwent reoperation due to hemoper-
itoneum and 1 patient had a wound abscess (Table 2).
4. Response to splenectomy and predictors of response
  The overall response rate to splenectomy was 84% with 
CR in 14 and PR in 12. The response rate at 6 and 12 
months was 77% and 68%, respectively. The long-term re-
sponse rate to splenectomy was 55%. Of the remaining pa-
tients, 35% relapsed and 10% were non-responders (Table 
3). Nine patients relapsed within 24 months after splenec-
tomy and 2 patients relapsed at 70 and 104 months. The 
median time for the progression of survival after splenectomy 
was 70 months (Fig. 1). In the 26 patients that responded 
to splenectomy, the curve of the proportion of patients re-
maining in remission plateaued after 9 months in the CR 
group; however, this rate continuously decreased in the PR 
group, in which the median time between splenectomy and 
relapse was 19 months (Fig. 2).
  There was no statistically significant difference between 
the responders (CR+PR) and non-responders with regard 
to gender, platelet counts at diagnosis, time to splenectomy, 
platelet counts before splenectomy, weight of the spleen, 
severity of symptoms at diagnosis, initial response to medical 
treatment, anti-platelet antibody, reasons for splenectomy, 
and method of splenectomy (Table 4).
5. Treatment of patients after splenectomy failure
  At 1 month after surgery, 5 patients were non-responsive 
to the splenectomy; 1 patient maintained platelet counts 
over 30×10
9/L and was observed without further treatment. 
One other patient achieved CR after 1 month without oral 
corticosteroid. The remaining 3 patients achieved PR or CR 
with oral corticosteroids only.
  Eleven patients relapsed during the median of 6 years 
of follow-up. One patient was non-responsive to splenec-
tomy, but his platelet counts were maintained over 30×10
9/L 
and he was observed without further treatment. Prednisone 
with or without IVIG was the most commonly used treatment 
and achieved CR (N=1) and PR (N=5). Danazol with or with-
out IVIG was the second most common treatment and ach-
ieved CR (N=1) and PR (N=2). The remaining patients ach-
ieved PR with vincristine after failing to respond to oral 
steroids, IVIG and danazol treatment. Three of the 11 relaps-
ing patients maintained their response when treatment ta-
pered off after the long-term follow-up (Table 5).
6. Morbidity and mortality
  Two patients (6%) died during follow-up. One patient 
had coronary artery disease before the diagnosis of ITP and 
achieved PR 7 years after splenectomy. This patient was 
admitted to the hospital with congestive heart failure and 
pulmonary edema; the cause of death was ventricular 
fibrillation. Another patient had a primary closure of the 
perforation of duodenal ulcer. This patient achieved PR to 
splenectomy, but relapsed after 1 year and achieved PR at Korean J Hematol 2010;45:197-204.
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  Male     3 (18)     1 (7)
  Female   14 (82)   13 (93)
Age at diagnosis (years)   38 (14-74)   50 (23-69) 0.222
Age at splenectomy (years)   43 (16-74)   51 (23-72) 0.235
Severity of symptoms at diagnosis 0.204
  Asymptomatic     2 (12)     6 (43)
  Minor skin purpura   10 (59)     5 (36)
  Clinically significant bleeding     5 (29)     3 (21)
Anti-platelet antibody 0.799
  Positive     3 (18)     4 (29)
  Negative     9 (53)     7 (50)
  Unknown     5 (39)     3 (21)
Response to initial medical treatment 0.553
  Complete response     4 (24)     1 (7)
  Partial response     8 (47)     7 (50)
  No response     5 (29)     6 (43)
Method of splenectomy 0.200
  Open   10 (59)     5 (36)
  Laparoscopy     7 (41)     9 (64)
Reasons for splenectomy 0.542
  Non-responders or relapsed   12 (70)     9 (64)
  Adverse effects to steroid     2 (12)     3 (22)
  Noncompliance to steroid     2 (12)     0 (0)
  Others     1 (6)     2 (14)
Platelet count at diagnosis (×10
9/L)   11 (1-45)   15 (2-72) 0.118
Platelet count before splenectomy (×10
9/L)      7 (1-77)   10 (1-33) 0.463
Time to splenectomy (months)   10 (0-155)     5 (0-56) 0.313
Weight of spleen (gram) 105 (52-222) 110 (37-400) 0.457
Median (range).
a)Patients who achieved complete response and partial response at long-term follow-up after splenectomy were included.
10 years after splenectomy. The cause of death was dis-
seminated intravascular coagulopathy after primary closure.
  Two patients that underwent laparoscopic splenectomy 
had reoperation due to hemoperitoneum. One patient was 
admitted to the hospital 1 month after an open splenectomy 
due to a wound abscess. A 17-year-old woman had over-
whelming post-splenectomy infection approximately 18 
months after a laparoscopic splenectomy. This patient was 
admitted due to a changed mental status, and was diagnosed 
with meningococcal meningitis. Four patients had other, 
newly developed medical problems after the splenectomy: 
steroid-induced severe acne, bilateral total hip replacements 
due to avascular necrosis of the femoral head, lupus nephritis, 
and coronary stent insertion due to unstable angina.
DISCUSSION
  Spleen is the major site of removal of immunized or dam-
aged RBCs, WBCs, and platelets that contribute to cytopenia. 
For this reason, splenectomy has been used as therapy for 
patients with ITP or hemolytic anemia. For the patients 
with ITP who were not responsive to initial corticosteroid 
therapy, splenectomy could be effective and curative [2, 
7, 10]. In this study, the response rate to splenectomy was 
84% at 1 month after the splenectomy. The initial response 
rate of this study was similar to that of the prior reports 
[9, 11-18]. However, the response rate decreased to 77% 
at 6 months after the splenectomy and further decreased 
to 68% at 12 months and 55% at the last follow-up. This 
data is consistent with the findings reported by other studies 
with 57-65% response rates after more than 5 years of 
post-splenectomy follow-up [17-19]. Some studies reporting 
higher long-term response rate, averaging 72-89%, had a 
median follow-up duration of less than 5 years. This study 
included only 13% males compared to over 25% males in 
other studies with higher response rates [9, 13, 14, 16]. In 
addition, the patients in this study might include more severe 
ITP patients; this explains the difference in the long-term 
responses [20, 21]. Recent studies reported that relapse con-
tinued to occur during the first 2-4 years after splenectomy 
[11, 14, 17, 22]. In this study, all the relapsed patients except 
for 2 had relapsed in the first 24 months after splenectomy.
  The difference in the duration of remission between the 
CR and PR patients was statistically significant (P=0.003). 
No relapse occurred in patients with CR since 9 months 
after the splenectomy. However, patients in the PR group 
continuously relapsed during the follow-up period; the me-Korean J Hematol 2010;45:197-204.
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Status at last follow-up
  1 F 25 Relapse Prednisone+IVIG PR   5 129,000 Admitted five times due
 to ITP symptoms
Dependent on therapy
  2 F 32 Relapse Prednisone+Danazol+IVIG PR 14   77,000 On therapy
  3 F 30 Relaspe Prednisone PR   6   76,000 Dependent on therapy
  4 M 39 Non-responder Prednisone CR   4 580,000 Off therapy, Use mesalazine
 due to ulcerative colitis 
  5 F 51 Relapse Prednisone PR   7   84,000 Off therapy
  6 F 61 Relapse Prednisone+Danazol+IVIG CR 13 504,000 On therapy
  7 F 30 Relapse None NR   1   34,000 Observation without treatment
  8 F 72 Relapse MPD PR   3   91,000 Off therapy
  9 F 55 Relapse Prednisone+Danazol PR   3   41,000 Dependent on therapy
10 F 51 Non-responder Prednisone PR   1   75,000 Off therapy
11 F 26 Non-responder None PR   8   87,000 Observation without treatment
12 F 69 Relapse Prednisone+IVIG CR   3 339,000 Admitted three times due
 to ITP symptoms 
Off therapy
13 F 69 Relapse Prednisone PR 11 136,000 Died of DIC after duodenal
 ulcer operation
a)
14 F 69 Relapse MPD+Danazol+IVIG+Vincristine PR   2   43,000 Dependent on vincristine
a)The cause of death was spontaneous bleeding associated with disseminated intravascular coagulopathy after surgery due to duodenal ulcer
perforation.
Abbreviations: MPD, methylprenisolone; CR, complete response; PR, partial response; NR, no response; ITP, immune thrombocytopenic 
purpura; DIC, disseminated intravascular coagulopathy.
dian time for relapse was 19 months. Johansson et al. also 
reported a plateau in the progression-free survival curve; 
however, there was no disease progression after 12.1 and 
7.3 years in patients with CR or PR, respectively [22]. Patients 
that achieved PR after splenectomy may have an unstable 
disease status and show a different clinical course in compar-
ison to patients that achieved CR after splenectomy. Further 
studies are needed to determine the long-term clinical course 
of patients that achieve PR to splenectomy.
  Various predictors of response to splenectomy, such as 
age, gender, duration of illness, response to steroids, pre-
operative platelet counts, severity of bleeding, and anti-plate-
let antibody were studied. In previous studies, younger age 
was the most common variable associated with a good re-
sponse to splenectomy; however, there was no specific age 
cutoff point that defined the younger group of patients [3, 
12-14]. Age was not a predictive factor in this study. In 
this study, there was no statistically significant difference 
between the response group and non-response group with 
regard to gender, platelet counts at diagnosis, time to splenec-
tomy, the lowest platelet counts before splenectomy, weight 
of the spleen, severity of symptoms at diagnosis, initial re-
sponse to medical treatment, anti-platelet antibody, reasons 
for splenectomy, and methods of splenectomy. Patients that 
underwent splenectomy were at increased risk for over-
whelming infection and death [15, 22, 23]. The complication 
rate after splenectomy was 13% (N=4); 2 patients had hemo-
peritoneum after laparoscopic splenectomy, 1 patient had 
a wound abscess after an open splenectomy, and 1 patient 
had an overwhelming infection 18 months after laparoscopic 
splenectomy. Four additional patients (13%) developed other 
medical problems. Portielje et al. reported that patients with 
ITP who underwent splenectomy had a postoperative com-
plication rate of 33% [23]. The complication rates in the 
study by Kojouri et al. were 13% with laparotomy and 10% 
with laparoscopic splenectomy [3]. Laparoscopic splenec-
tomy is now more widely used than open splenectomy; how-
ever, there is no proof that laparoscopic splenectomy is safer 
than open splenectomy [3, 10, 23].
  In this study, patients with platelet counts less than 
50×10
9/L were considered non-responsive or in relapse after 
splenectomy. This might have included many patients who 
might not have required treatment. Three patients in the 
current study were observed without treatment. The platelet 
counts in these patients remained over 30×10
9/L during the 
follow-up, with no significant bleeding. Patients with platelet 
counts more than 30×10
9/L have a minimal risk of severe 
bleeding, and may be safely observed without treatment 
with more severe thrombocytopenia [23-25].
  Although only 55% of patients were considered responders 
to splenectomy during the long-term follow-up, most non-
responsive patients achieved CR or PR with additional 
treatment. Other studies have reported similar results; that 
is, most patients that had refractory ITP or relapsed after 
splenectomy achieved good responses to additional treatment 
[26, 27]. Two of the 4 non-responders achieved CR or PR 
without any treatment. Three of the 11 patients that relapsed 
after splenectomy also achieved CR or PR without any Korean J Hematol 2010;45:197-204.
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treatment. The suppression of platelet production can play 
a role in the pathogenesis of ITP, and removal of the spleen 
might be the most effective therapy for some patients with 
ITP.
  According to the Maastricht III consensus conference, de-
tection and eradication of Helicobacter pylori (H. pylori) 
is indicated in patients with ITP [28]. With H. pylori erad-
ication, CR and overall response of 42.7% and 50.3% has 
been reported [29]. The response rate tended to be higher 
in countries with a high prevalence of H. pylori [29]. H. 
pylori infection was not evaluated in this study. The associa-
tion between H. pylori and ITP requires further study.
  In conclusion, splenectomy may be considered as safe and 
effective for patients with ITP who failed to respond to 
first-line corticosteroid treatment. However, the initial re-
sponse rate continuously decreases over time. The duration 
o f  re spo n se  is d if f e ren t  in  pat ien t s t h at  ac h ie v ed  C R  and  
those that achieved PR during long-term follow-up after 
splenectomy, and most of them relapsed in the first 2 years 
after splenectomy. Additional treatment in patients who did 
not respond or relapsed after splenectomy was mostly effec-
tive, with some patients in this group sustaining a response 
without any treatment. None of the factors, including age, 
were reliable in identifying patients who are likely to respond 
to splenectomy.
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